Arrowstreet Capital Limited Partnership reduced its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 18.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 279,893 shares of the company's stock after selling 61,971 shares during the period. Arrowstreet Capital Limited Partnership's holdings in Sanofi were worth $13,499,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in SNY. Charles Schwab Investment Management Inc. raised its stake in shares of Sanofi by 31.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company's stock worth $8,040,000 after purchasing an additional 33,105 shares during the last quarter. Arkadios Wealth Advisors grew its stake in shares of Sanofi by 19.0% during the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock valued at $227,000 after acquiring an additional 751 shares during the period. Geode Capital Management LLC boosted its position in shares of Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock worth $14,681,000 after purchasing an additional 16,780 shares during the period. JPMorgan Chase & Co. boosted its holdings in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock worth $133,172,000 after buying an additional 399,301 shares during the period. Finally, Kentucky Trust Co bought a new position in shares of Sanofi in the fourth quarter worth about $436,000. 14.04% of the stock is owned by hedge funds and other institutional investors.
Sanofi Stock Performance
Shares of NASDAQ SNY traded down $0.51 during trading hours on Tuesday, reaching $50.25. The stock had a trading volume of 1,885,760 shares, compared to its average volume of 2,292,661. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The firm has a market cap of $127.52 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 1.01 and a beta of 0.57. The firm has a 50-day moving average of $55.32 and a 200-day moving average of $52.60.
Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities research analysts predict that Sanofi will post 4.36 earnings per share for the current year.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the stock. Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. The Goldman Sachs Group assumed coverage on Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 target price on the stock. StockNews.com cut shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $62.50.
Read Our Latest Analysis on SNY
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Featured Stories
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
